KMT2A is a prerequisite of malignant transformation during IDH-mutant gliomagenesis. Koch MS, Deo M, Schmidt C, Podolak A, et al. Neuro Oncol 2026 Jan 14:noag006. doi: 10.1093.

Read + Share

Amedeo Smart

Independent Medical Education

Koch MS, Deo M, Schmidt C, Podolak A, et al. KMT2A is a prerequisite of malignant transformation during IDH-mutant gliomagenesis. Neuro Oncol 2026 Jan 14:noag006. doi: 10.1093.
PMID: 41537229